Spruce Street Capital »

Athira Pharma shares owned by Spruce Street Capital

Quarter-by-quarter ownership of Athira Pharma (LONA) shares owned by Spruce Street Capital from 13F filings

Historical chart of Spruce Street Capital investment in Athira Pharma

Tip: Access up to 7 years of quarterly data

All positions including Athira Pharma held by Spruce Street Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Athira Pharma by Spruce Street Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $3.6M 394k 9.19

More positions owned by Spruce Street Capital

Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Relay Therapeutics (RLAY)
Lb Pharmaceuticals Com Shs (LBRX)
Relmada Therapeutics (RLMD)
Alto Neuroscience Com Shs (ANRO)
Dianthus Therapeutics (DNTH)
Alkermes SHS (ALKS)
Savara (SVRA)
Vaxcyte (PCVX)
Enliven Therapeutics (ELVN)
Enanta Pharmaceuticals (ENTA)
Perspective Therapeutics Com New (CATX)
Inflarx Nv (IFRX)
Surrozen Com New (SRZN)
Alumis (ALMS)

View all positions for Spruce Street Capital

Top funds holding Athira Pharma

Perceptive Advisors
ADAR1 Capital Management
Acorn Capital Advisors
Commodore Capital
TCG Crossover Management
NEA Management Company
Spruce Street Capital
Kalehua Capital Management
Vanguard Capital Management
Seven Fleet Capital Management
Propel Bio Management
Simplify Asset Management
Geode Capital Management
Renaissance Technologies
BlackRock

View all funds holding Athira Pharma